omeprazole and Zollinger-Ellison Syndrome studies

Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.

Zollinger-Ellison Syndrome: A syndrome that is characterized by the triad of severe PEPTIC ULCER, hypersecretion of GASTRIC ACID, and GASTRIN-producing tumors of the PANCREAS or other tissue (GASTRINOMA). This syndrome may be sporadic or be associated with MULTIPLE ENDOCRINE NEOPLASIA TYPE 1.

Research Excerpts

Excerpt	Relevance	Reference
"The safety and efficacy data for short-term (6-month) treatment of Zollinger-Ellison syndrome and idiopathic hypersecretion with oral pantoprazole were previously published."	9.12	Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. ( Chey, W; Comer, GM; Cryer, B; Forsmark, CE; Metz, DC; Pisegna, JR; Soffer, E, 2006)
"Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7."	9.11	Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005)
"In this open prospective study, the efficacy of pantoprazole in reducing gastric acid secretion in Zollinger-Ellison syndrome patients was compared to that obtained previously with other proton pump inhibitors."	9.10	Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. ( Mignon, M; Ramdani, A; Samoyeau, R, 2002)
"The aim of this prospective study was to confirm the efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome (ZES)."	9.08	[Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment]. ( Cadiot, G; Coste, T; Escourrou, J; Forestier, S; Mignon, M; Pospaï, D; Ruszniewski, P, 1998)
"Lansoprazole was given for 3-48 months (median 28 months) to 26 Zollinger-Ellison syndrome patients with peptic ulcer manifestations in all and oesophagitis in 13."	9.08	Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. ( Hirschowitz, BI; Mohnen, J; Shaw, S, 1996)
"We report long-term, up to 4 years, prospective treatment using lansoprazole in nine male patients with duodenal ulcers and a BAO of more than 15 mmol/h whose results are compared with those in 10 male Zollinger-Ellison syndrome patients with intact stomachs reported in detail in an accompanying paper."	9.08	Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. ( Hirschowitz, BI; Mohnen, J; Shaw, S, 1996)
"Lansoprazole, a new substituted benzimidazole H+,K(+)-ATPase inhibitor, profoundly inhibits gastric acid secretion and has potential use in the management of diseases such as Zollinger-Ellison syndrome (ZES)."	9.07	Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. ( Feigenbaum, K; Gardner, JD; Jensen, RT; Koviack, PD; Maton, PN; Metz, DC; Pisegna, JR; Ringham, GL, 1993)
"H+, K(+)-ATPase inhibitors such as omeprazole are the antisecretory agents of choice for the management of gastric acid hypersecretory states, including the Zollinger-Ellison syndrome."	9.07	Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. ( Feigenbaum, KM; Jensen, RT; Koviack, PD; Metz, DC; Orbuch, M; Strader, DB, 1993)
"The pharmacokinetics and pharmacodynamics of oral and IV omeprazole after a single dose were studied in 9 patients with the Zollinger-Ellison syndrome to determine whether the increased dose required to control gastric acid hypersecretion could be explained on the basis of altered pharmacokinetics."	9.07	Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. ( Amantea, MA; Frucht, H; Gardner, JD; Jensen, RT; Maton, PN; Vinayek, R, 1991)
"The long-term safety and efficacy of lansoprazole were studied in 21 patients with Zollinger-Ellison syndrome."	9.07	Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. ( Feigenbaum, KM; Jensen, RT; Koviack, PD; Metz, DC, 1993)
"Omeprazole, a substituted benzimidazole, has been shown to be a potent inhibitor of gastric acid secretion in patients with Zollinger-Ellison syndrome (ZES)."	8.78	Use of omeprazole in patients with Zollinger-Ellison syndrome. ( Frucht, H; Jensen, RT; Maton, PN, 1991)
" pantoprazole therapy at a dose of 80-240 mg/day in divided doses was both effective and generally well tolerated for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion."	7.72	Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. ( Bochenek, W; Chey, W; Cryer, B; Forsmark, CE; Metz, DC; Pisegna, JR; Soffer, E, 2003)
" pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole."	7.71	Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001)
"The proton pump inhibitors (omeprazole and lansoprazole) are the drugs of choice for the medical management of gastric acid hypersecretion in Zollinger-Ellison syndrome (ZES)."	7.69	A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. ( Gibril, F; Jensen, RT; Stewart, CA; Termanini, B; Weber, HC, 1996)
"The efficacy of omeprazole increases during the first few days of administration, suggesting that long-term maintenance dose requirements in patients with Zollinger-Ellison syndrome may be lower than those initially established by upward titration."	7.68	Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. ( Benya, RV; Feigenbaum, KM; Fishbeyn, VA; Jensen, RT; Koviack, PD; Metz, DC; Pisegna, JR, 1992)
"Evolution of gastrinoma tumoral mass, fasting serum gastrin concentrations, and gastric endocrine cells has been analyzed in 21 patients with the Zollinger-Ellison syndrome committed to long-term omeprazole treatment (up to 7."	7.68	Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment. ( Bonfils, S; Cadiot, G; Lehy, T; Mignon, M; Ruszniewski, P, 1993)
"Development of focal gland atrophy of the oxyntic mucosa was found in two patients with the Zollinger-Ellison syndrome undergoing long-term treatment with omeprazole."	7.68	Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger-Ellison syndrome during omeprazole treatment. ( Annibale, B; Azzoni, C; Bertelé, A; Bordi, C; Caruana, P; Delle Fave, G; Franzé, A, 1992)
"Twenty patients with Zollinger-Ellison syndrome who were undergoing surgery were studied prospectively to assess the efficacy and safety of IV omeprazole."	7.68	Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. ( Cederberg, C; Frucht, H; Gardner, JD; Jensen, RT; London, JF; Maton, PN; Miller, LS; Norton, JA; Stark, HA; Vinayek, R, 1990)
"Treatment with omeprazole was evaluated in nine patients with the Zollinger-Ellison syndrome, in whom the effect of H2-receptor antagonists had become inadequate."	7.67	Omeprazole in the Zollinger-Ellison syndrome. ( Bardram, L; Stadil, F, 1986)
"The inhibitory effect of omeprazole, a benzimidazole derivative, on gastric acid secretion was investigated in seven patients with Zollinger-Ellison syndrome resistant to treatment with large doses of histamine H2-receptor antagonists administered alone or in combination with pirenzepine."	7.67	Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists. ( Bader, JP; Cortot, A; Delchier, JC; Goldfain, D; Isal, JP; Mignon, M; Soule, JC; Travers, B, 1986)
"To determine the long-term efficacy, safety, and toxicity of omeprazole, we studied 40 patients with Zollinger-Ellison syndrome given omeprazole for 6-51 mo (median 29)."	7.67	Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. ( Frucht, H; Gardner, JD; Jensen, RT; Maton, PN; McArthur, KA; Miller, LS; Saeed, ZA; Vinayek, R, 1989)
"The acute and long-term effects of omeprazole on gastric acid secretion were examined in 11 patients with Zollinger-Ellison syndrome."	7.67	Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. ( Cherner, JA; Ciarleglio, CA; Collen, MJ; Cornelius, MJ; Gardner, JD; Howard, JM; Jensen, RT; Maton, PN; McArthur, KE, 1985)
"Omeprazole, a powerful and long-lasting gastric anti-secretory benziimidazole derivative has been used to treat a particularly severe case of Zollinger-Ellison syndrome with familial type I multiple endocrine involvement."	7.67	[Gastric secretory, ultrastructural and pH changes during prolonged treatment with omeprazole in a severe form of Zollinger-Ellison syndrome]. ( Alcabes, G; Bonfils, S; Lehy, T; Mignon, M; Nguyen Phuoc, BK; Vatier, J, 1984)
"The H+, K(+)-ATPase inhibitor omeprazole has been made available on a compassionate basis for patients with Zollinger-Ellison syndrome considered resistant to, or with side-effects on, histamine H2-receptor antagonists."	7.67	Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. ( Lloyd-Davies, KA; Rutgersson, K; Sölvell, L, 1988)
"We studied the effect of omeprazole, a benzimidazole inhibitor of gastric acid secretion, in patients with Zollinger-Ellison syndrome."	7.67	Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists. ( Jansen, JB; Lambers, CB; Lind, T; Moberg, S; Olbe, L, 1984)
"Endoscopic biopsies were taken from the oxyntic mucosa in patients with duodenal ulcer (DU) before and after 4 weeks of treatment with omeprazole."	7.67	Oxyntic mucosa histology in omeprazole-treated patients suffering from duodenal ulcer or Zollinger-Ellison syndrome. ( Helander, HF, 1986)
"Omeprazole is a very potent and long-acting inhibitor of gastric acid secretion."	6.38	Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers. ( Jansen, JB; Lamers, CB; Meijer, JL, 1989)
"Omeprazole is a substituted benzimidazole derivative which markedly inhibits basal and stimulated gastric acid secretion."	6.37	Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. ( Campoli-Richards, DM; Clissold, SP, 1986)
"More than 13,000 individuals with duodenal ulcer, gastric ulcer or reflux oesophagitis have now taken part in controlled clinical studies with omeprazole."	6.16	The clinical utility and safety of omeprazole. ( Walan, A, 1989)
"pantoprazole was evaluated in 14 ZES patients."	5.31	Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. ( Bochenek, W; Forsmark, C; Lew, EA; Metz, DC; Pisegna, JR; Soffer, EF; Starr, JA, 2001)
"Pantoprazole was administered at an initial dose of 80 mg daily for seven days before basal acid output (BAO) was measured at 08:00, ie, 1 h before the next dose of pantoprazole was normally ingested."	5.31	Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome. ( Désir, B; Poitras, P, 2001)
"Omeprazole 60 mg/day was administered to these 8 patients; after one month, the dose was reduced to 40 mg/day, and after another month to 20 mg/day."	5.29	Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients. ( Annibale, B; Cassetta, MR; Corleto, V; D'Ambra, G; Delle Fave, G; Ferrua, B; Saggioro, A, 1993)
"Omeprazole is a potent and long-acting inhibitor of pentagastrin stimulated gastric acid secretion in normal subjects, and this prompted a study of the effect of omeprazole on gastric acid hypersecretion and acid peptic disease resulting from endogenous hypergastrinaemia in Zollinger-Ellison patients."	5.27	Present experiences with omeprazole in the Zollinger-Ellison syndrome. ( Lamers, CB, 1986)
"The safety and efficacy data for short-term (6-month) treatment of Zollinger-Ellison syndrome and idiopathic hypersecretion with oral pantoprazole were previously published."	5.12	Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. ( Chey, W; Comer, GM; Cryer, B; Forsmark, CE; Metz, DC; Pisegna, JR; Soffer, E, 2006)
"Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7."	5.11	Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005)
"In this open prospective study, the efficacy of pantoprazole in reducing gastric acid secretion in Zollinger-Ellison syndrome patients was compared to that obtained previously with other proton pump inhibitors."	5.10	Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. ( Mignon, M; Ramdani, A; Samoyeau, R, 2002)
" Pentagastrin was infused continuously in healthy subjects as a model for patients with Zollinger-Ellison syndrome."	5.09	Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study. ( Martin, P; McKeand, W; Ohning, G; Paul, J; Pisegna, JR; Walsh, JH, 1999)
"We report long-term, up to 4 years, prospective treatment using lansoprazole in nine male patients with duodenal ulcers and a BAO of more than 15 mmol/h whose results are compared with those in 10 male Zollinger-Ellison syndrome patients with intact stomachs reported in detail in an accompanying paper."	5.08	Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. ( Hirschowitz, BI; Mohnen, J; Shaw, S, 1996)
"Lansoprazole was given for 3-48 months (median 28 months) to 26 Zollinger-Ellison syndrome patients with peptic ulcer manifestations in all and oesophagitis in 13."	5.08	Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. ( Hirschowitz, BI; Mohnen, J; Shaw, S, 1996)
"The aim of this prospective study was to confirm the efficacy and safety of lansoprazole in patients with Zollinger-Ellison syndrome (ZES)."	5.08	[Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment]. ( Cadiot, G; Coste, T; Escourrou, J; Forestier, S; Mignon, M; Pospaï, D; Ruszniewski, P, 1998)
"The long-term safety and efficacy of lansoprazole were studied in 21 patients with Zollinger-Ellison syndrome."	5.07	Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. ( Feigenbaum, KM; Jensen, RT; Koviack, PD; Metz, DC, 1993)
"This paper aimed at evaluating the comparative efficacy of lansoprazole and omeprazole in reducing gastric acid secretion in patients suffering from Zollinger-Ellison syndrome."	5.07	[Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal]. ( Cadiot, G; Forestier, S; Joubert-Collin, M; Mignon, M; Paul, G; Ramdani, A; Ruszniewski, P; Vallot, T, 1994)
"Lansoprazole, a new substituted benzimidazole H+,K(+)-ATPase inhibitor, profoundly inhibits gastric acid secretion and has potential use in the management of diseases such as Zollinger-Ellison syndrome (ZES)."	5.07	Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. ( Feigenbaum, K; Gardner, JD; Jensen, RT; Koviack, PD; Maton, PN; Metz, DC; Pisegna, JR; Ringham, GL, 1993)
"H+, K(+)-ATPase inhibitors such as omeprazole are the antisecretory agents of choice for the management of gastric acid hypersecretory states, including the Zollinger-Ellison syndrome."	5.07	Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. ( Feigenbaum, KM; Jensen, RT; Koviack, PD; Metz, DC; Orbuch, M; Strader, DB, 1993)
" Clinical trials of omeprazole, a substituted benzimidazole, indicate that it is safe and effective for short-term treatment of patients with duodenal or gastric ulcer, and it is highly effective for long-term treatment of patients with Zollinger-Ellison syndrome."	5.06	Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase. ( Gardner, JD; Jensen, RT; McArthur, KE, 1986)
"Esomeprazole (Nexium); S-omeprazole) is a single optical isomer proton-pump inhibitor (PPI) approved for the management of reflux oesophagitis, the symptomatic treatment of gastro-oesophageal reflux disease (GORD), the prevention and healing of NSAID-associated gastric ulcer disease (and the prevention of NSAID-associated duodenal ulcers in the UK), the treatment of Helicobacter pylori infection and associated duodenal ulcer disease (and prevention of relapse of H."	4.84	Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. ( Blick, SK; Croxtall, JD; Keating, GM; Lyseng-Williamson, KA; McKeage, K, 2008)
" In 8-week studies, among patients with gastro-oesophageal reflux disease (GORD), rabeprazole 20 mg/day or 10mg twice daily was as effective as omeprazole and superior to ranitidine in the healing of GORD."	4.81	Rabeprazole: an update of its use in acid-related disorders. ( Carswell, CI; Goa, KL, 2001)
"Aim of this overview was to evaluate the main clinical trials with lansoprazole published from 1997 to 1999 in English-language journals, regarding gastroesophageal reflux disease, peptic ulcer, NSAID-induced ulcer, and ZES."	4.80	[Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999]. ( Capurso, L; Dobrilla, G, 2000)
"To summarize the published data on lansoprazole, a proton pump inhibitor approved by the Food and Drug Administration for use in the treatment of duodenal ulcer, erosive esophagitis, and pathologic hypersecretory conditions (e."	4.79	Lansoprazole: a proton pump inhibitor. ( Garnett, WR, 1996)
"Several histamine H2 receptor antagonists and the H+,K(+)-ATPase inhibitor, omeprazole, have been shown to be capable of controlling gastric acid secretion safely and effectively in patients with Zollinger-Ellison syndrome."	4.77	Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. ( Gardner, JD; Jensen, RT; Maton, PN, 1989)
"Lansoprazole is an effective acid pump inhibitor acting at the final enzymatic step of the acid secretory pathway of the parietal cell, decreasing gastric acid secretion regardless of the primary stimulus."	3.77	Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. ( Barradell, LB; Faulds, D; McTavish, D, 1992)
"Omeprazole, which has a long duration of action and is a potent inhibitor of gastric acid secretion, has simplified management."	3.77	Role of acid suppressants in patients with Zollinger-Ellison syndrome. ( Maton, PN, 1991)
"Omeprazole has given healing rates of 58-83% after treatment for 2 weeks and 84-100% after 4 weeks."	3.76	Clinical experience with omeprazole: assessment of efficacy and safety. ( Walan, A, 1989)
" Isolated, non-specific adverse events which might be attributable to omeprazole have included nausea, dizziness, headache and diarrhoea."	3.76	The clinical safety of omeprazole. ( Sölvell, L, 1990)
" pantoprazole therapy at a dose of 80-240 mg/day in divided doses was both effective and generally well tolerated for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion."	3.72	Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. ( Bochenek, W; Chey, W; Cryer, B; Forsmark, CE; Metz, DC; Pisegna, JR; Soffer, E, 2003)
"To determine the efficacy of lansoprazole control of acid and pepsin secretion over the long term in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome hypersecretors."	3.71	Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2001)
" pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole."	3.71	Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001)
"The efficacy of omeprazole increases during the first few days of administration, suggesting that long-term maintenance dose requirements in patients with Zollinger-Ellison syndrome may be lower than those initially established by upward titration."	3.68	Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. ( Benya, RV; Feigenbaum, KM; Fishbeyn, VA; Jensen, RT; Koviack, PD; Metz, DC; Pisegna, JR, 1992)
" Hyperpepsinogenaemia A has been shown in patients with duodenal ulcer disease, Zollinger-Ellison syndrome, hypertrophic gastropathy, chronic renal failure, and during omeprazole treatment."	3.68	Diagnostic value of serum pepsinogen C in patients with raised serum concentrations of pepsinogen A. ( Biemond, I; Jansen, JB; Kreuning, J; Lamers, CB, 1993)
"Biopsy specimens from the oxyntic mucosa were obtained on 210 occasions from 76 patients with the Zollinger-Ellison syndrome (ZES) before and during omeprazole treatment."	3.68	Stereologic investigations of human gastric mucosa. II. Oxyntic mucosa from patients with Zollinger-Ellison syndrome. ( Gardner, JD; Helander, HF; Helander, KG; Jensen, RT; Maton, PN; Pisegna, JP; Rutgersson, K, 1992)
"Evolution of gastrinoma tumoral mass, fasting serum gastrin concentrations, and gastric endocrine cells has been analyzed in 21 patients with the Zollinger-Ellison syndrome committed to long-term omeprazole treatment (up to 7."	3.68	Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment. ( Bonfils, S; Cadiot, G; Lehy, T; Mignon, M; Ruszniewski, P, 1993)
"We studied the effect of omeprazole, a benzimidazole inhibitor of gastric acid secretion, in patients with Zollinger-Ellison syndrome."	3.67	Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists. ( Jansen, JB; Lambers, CB; Lind, T; Moberg, S; Olbe, L, 1984)
"The inhibitory effect of omeprazole, a benzimidazole derivative, on gastric acid secretion was investigated in seven patients with Zollinger-Ellison syndrome resistant to treatment with large doses of histamine H2-receptor antagonists administered alone or in combination with pirenzepine."	3.67	Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists. ( Bader, JP; Cortot, A; Delchier, JC; Goldfain, D; Isal, JP; Mignon, M; Soule, JC; Travers, B, 1986)
"Endoscopic biopsies were taken from the oxyntic mucosa in patients with duodenal ulcer (DU) before and after 4 weeks of treatment with omeprazole."	3.67	Oxyntic mucosa histology in omeprazole-treated patients suffering from duodenal ulcer or Zollinger-Ellison syndrome. ( Helander, HF, 1986)
"Omeprazole is a substituted benzimidazole which inhibits profoundly and long-lasting human acid secretion."	2.66	[Omeprazole in the therapy of acid-induced diseases]. ( Dammann, HG; Müller, P; Simon, B, 1987)
" The incidence of serious adverse events reported in comparative short-term studies with H2-receptor antagonists and placebo were similar."	2.66	The clinical safety of omeprazole. ( Sölvell, L, 1989)
"Pantoprazole (Protonix) is an irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion."	2.42	Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. ( Cheer, SM; Faulds, D; Lamb, HM; Prakash, A, 2003)
" Another advantage over the histamine 2 receptor antagonists is that pantoprazole does not require dosage adjustment in patients with renal impairment."	2.41	Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression. ( Trépanier, EF, 2000)
" Intravenous pantoprazole is especially distinguished in its lack of clinically relevant drug interactions, and it requires no dosage adjustment for patients with renal insufficiency or with mild to moderate hepatic dysfunction."	2.41	Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. ( Metz, DC, 2000)
" The superior acid control achieved by esomeprazole is mainly due to an advantageous metabolism compared with racemate omeprazole, leading to improved bioavailability and to enhanced delivery of the drug to the gastric proton pump."	2.41	Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. ( Savarino, V; Scarpignato, C; Tonini, M; Vigneri, S, 2001)
"Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells."	2.41	An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002)
"Patients with multiple endocrine neoplasia Type I (MEN-I) and ZES become symptomatic at an earlier age than patients with sporadic ZES."	2.39	Management of patients with Zollinger-Ellison syndrome. ( Meko, JB; Norton, JA, 1995)
"Omeprazole has been shown to give significantly higher healing rates than ranitidine or cimetidine in patients with duodenal ulcer and gastric ulcer."	2.38	Clinical utility and safety of omeprazole. ( Walan, A, 1989)
"argyrophilic gastric carcinoids."	2.38	Enterochromaffin-like (ECL) cells and their growths: relationships to gastrin, reduced acid secretion and gastritis. ( Rindi, G; Silini, E; Solcia, E; Villani, L, 1993)
" Our group first performed a dose-response analysis of the efficacy of lansoprazole in reducing basal acid output (BAO) in four patients with severe Zollinger-Ellison syndrome (mean BAO 52 +/- 9 [SD] mmol H+/h) who had previously been treated with a mean omeprazole dosage of 75 mg/day."	2.38	Treatment of patients with Zollinger-Ellison syndrome. ( Forestier, S; Mignon, M; Pospai, D; Vallot, T; Vatier, J, 1993)
"ECL-cell hyperplasia and carcinoids which occur during application of very high doses of omeprazole in rats are not caused by a direct effect of omeprazole."	2.38	[Risk for developing tumors in therapy with the proton pump inhibitor omeprazole]. ( Arnold, R; Eissele, R, 1993)
"Omeprazole is a very potent and long-acting inhibitor of gastric acid secretion."	2.38	Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers. ( Jansen, JB; Lamers, CB; Meijer, JL, 1989)
"Omeprazole is a substituted benzimidazole derivative which markedly inhibits basal and stimulated gastric acid secretion."	2.37	Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. ( Campoli-Richards, DM; Clissold, SP, 1986)
" Common causes were discarded and the hypomagnesaemia was attributed to chronic use of the proton pump inhibitor, omeprazole."	1.40	From hypomagnesaemia to Zollinger-Ellison syndrome: an adverse effect of a proton pump inhibitor. ( Braun, E; Eyal, A; Naffaa, ME; Sueissa, A, 2014)
"We examined 27 patients with hypochlorhydria or achlorhydria based on a predefined basal acid output (BAO) measurement of less than 5."	1.39	Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. ( Metz, DC; Shah, P; Singh, MH; Yang, YX, 2013)
"Primary lymph node gastrinomas are relatively rare in children and, to the best of our knowledge, have not previously been reported at this location."	1.37	Long-term follow-up of a child with primary lymph node gastrinoma and Zollinger-Ellison syndrome. ( Nazir, Z, 2011)
"Pantoprazole was administered at an initial dose of 80 mg daily for seven days before basal acid output (BAO) was measured at 08:00, ie, 1 h before the next dose of pantoprazole was normally ingested."	1.31	Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome. ( Désir, B; Poitras, P, 2001)
"Intramucosal cysts were found in biopsies of non-polypoid gastric body mucosa in 71."	1.31	Intramucosal cysts in the gastric body of patients with Zollinger-Ellison syndrome. ( Aprile, MR; Azzoni, C; Bordi, C; Gibril, F; Jensen, RT, 2000)
"pantoprazole was evaluated in 14 ZES patients."	1.31	Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. ( Bochenek, W; Forsmark, C; Lew, EA; Metz, DC; Pisegna, JR; Soffer, EF; Starr, JA, 2001)
"Whether such treatment will result in vitamin B12 deficiency is controversial."	1.30	Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. ( Gibril, F; Jensen, RT; Sutliff, VE; Termanini, B; Venzon, DJ; Yu, F, 1998)
"Cushing's syndrome was the result of ectopic adrenocorticotropic hormone production by a large cystic gastrin-producing tumour of the pancreatic tail."	1.30	Cushing's syndrome due to ectopic adrenocorticotropic hormone production by a non-metastatic gastrinoma after long-term conservative treatment of Zollinger-Ellison syndrome. ( Basenau, D; Becker, H; Horstmann, O; Raddatz, D; Ramadori, G, 1998)
"Omeprazole 60 mg/day was administered to these 8 patients; after one month, the dose was reduced to 40 mg/day, and after another month to 20 mg/day."	1.29	Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients. ( Annibale, B; Cassetta, MR; Corleto, V; D'Ambra, G; Delle Fave, G; Ferrua, B; Saggioro, A, 1993)
"However, reflux esophagitis is less well recognized."	1.28	Reflux esophagitis in patients with Zollinger-Ellison syndrome. ( Frucht, H; Gardner, JD; Jensen, RT; Maton, PN; Miller, LS; Vinayek, R, 1990)
"Omeprazole was well tolerated, and the incidence of clinical and laboratory adverse experiences was similar in patients receiving omeprazole, placebo, cimetidine, or ranitidine."	1.28	Comparative tolerability profile of omeprazole in clinical trials. ( Bradstreet, DC; Simon, TJ, 1991)
"Treatment with omeprazole also gave faster and more pronounced pain relief."	1.27	Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors. ( Walan, A, 1986)
"Omeprazole is a potent and long-acting inhibitor of pentagastrin stimulated gastric acid secretion in normal subjects, and this prompted a study of the effect of omeprazole on gastric acid hypersecretion and acid peptic disease resulting from endogenous hypergastrinaemia in Zollinger-Ellison patients."	1.27	Present experiences with omeprazole in the Zollinger-Ellison syndrome. ( Lamers, CB, 1986)
"Omeprazole has been given to more than 2500 subjects, mostly in short-term studies for 2-4 weeks, but also to some patients for more than 2 years."	1.27	Safety aspects of omeprazole. ( Sölvell, L, 1986)

Research

Studies (149)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Long-term Medical(Non-surgical)Control of Gastric Acid Production Assessed From Time of Study Enrollment, up to 240 Months Post Enrollment.

Timeframe	Studies, this research(%)	All Research%
pre-1990	42 (28.19)	18.7374
1990's	73 (48.99)	18.2507
2000's	30 (20.13)	29.6817
2010's	4 (2.68)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Norton, JA	5
Foster, DS	1
Blumgart, LH	1
Poultsides, GA	1
Visser, BC	1
Fraker, DL	2
Alexander, HR	1
Jensen, RT	23
Shah, P	1
Singh, MH	1
Yang, YX	1
Metz, DC	13
Eyal, A	1
Sueissa, A	1
Braun, E	1
Naffaa, ME	1
McKeage, K	1
Blick, SK	1
Croxtall, JD	1
Lyseng-Williamson, KA	1
Keating, GM	1
Nazir, Z	1
Cheer, SM	1
Prakash, A	1
Faulds, D	2
Lamb, HM	1
Leitner, A	1
Zöllner, P	1
Soffer, E	2
Forsmark, CE	2
Cryer, B	2
Chey, W	2
Bochenek, W	3
Pisegna, JR	9
Hage, E	1
Hendel, L	1
Gustafsen, J	1
Hendel, J	1
Scherübl, H	1
Schaaf, L	1
Raue, F	1
Faiss, S	1
Zeitz, M	1
Hirschowitz, BI	7
Simmons, J	3
Mohnen, J	5
Blonski, WC	1
Katzka, DA	1
Lichtenstein, GR	1
Comer, GM	1
Blanchi, A	1
Delchier, JC	2
Soule, JC	2
Payen, D	1
Bader, JP	2
Oberg, K	1
Lindström, H	1
Lambers, CB	1
Lind, T	2
Moberg, S	1
Jansen, JB	3
Olbe, L	2
Becker, HD	1
Fimmel, CJ	1
Blum, AL	1
Ashley, SW	1
Cheung, LY	1
Mignon, M	10
Alcabes, G	1
Lehy, T	3
Nguyen Phuoc, BK	1
Vatier, J	3
Bonfils, S	2
Rossi, G	1
Dítĕ, P	1
Prásek, J	1
Harper, MA	1
McVeigh, JE	1
Thompson, W	1
Ardill, JE	2
Buchanan, KD	2
Meko, JB	2
Solcia, E	2
Rindi, G	1
Silini, E	1
Villani, L	2
Cadiot, G	5
Hélie, C	1
Vallot, T	4
Marmuse, JP	1
Cosnes, J	1
Riché, A	1
Dutta, SK	1
Paul, G	1
Ramdani, A	2
Forestier, S	4
Ruszniewski, P	5
Joubert-Collin, M	2
Degtiareva, II	1
Semeunovich, S	1
Kharchenko, NV	1
Petrovich, S	1
Gaĭsenko, AV	1
Egorova, IT	1
Maton, PN	15
Arens, MJ	1
Dent, J	1
Arnold, R	4
Strader, DB	1
Orbuch, M	1
Koviack, PD	4
Feigenbaum, KM	3
Hochlaf, S	1
Seifert, E	1
Pospai, D	2
Biemond, I	1
Kreuning, J	1
Lamers, CB	5
Eissele, R	2
Ringham, GL	1
Feigenbaum, K	1
Gardner, JD	11
Protzer, U	1
Holtermüller, KH	1
McCloy, R	1
Nair, R	1
Corleto, V	1
Annibale, B	3
D'Ambra, G	1
Saggioro, A	1
Ferrua, B	1
Cassetta, MR	1
Delle Fave, G	3
Shaw, S	2
Termanini, B	3
Gibril, F	5
Stewart, CA	2
Weber, HC	2
Garnett, WR	1
Venzon, DJ	3
Franko, TG	1
Richter, JE	1
Sutliff, VE	2
Yu, F	2
Qureshi, W	1
Rashid, S	1
Serrano, J	2
Coste, T	1
Escourrou, J	1
Raddatz, D	1
Horstmann, O	1
Basenau, D	1
Becker, H	1
Ramadori, G	1
Martin, P	1
McKeand, W	1
Ohning, G	1
Walsh, JH	2
Paul, J	1
Martín de Argila, C	1
Boixeda de Miquel, D	1
Moreira Vicente, V	1
García Plaza, A	1
Aprile, MR	1
Azzoni, C	2
Bordi, C	2
Lew, EA	2
Starr, JA	2
Soffer, EF	2
Forsmark, C	2
Modlin, IM	1
Beg, M	1
Dobrilla, G	1
Capurso, L	1
Declich, P	1
Ambrosiani, L	1
Grassini, R	1
Tavani, E	1
Bellone, S	1
Bortoli, A	1
Gozzini, C	1
Prada, A	1
Trépanier, EF	1
Haber, MM	1
Waldum, HL	1
Maev, IV	1
V'iuchnova, ES	1
Lebedev, EG	1
Dicheva, DT	1
Ovsiannikova, EV	1
Antonenko, OM	1
Shchekina, MI	1
Corleto, VD	1
Angeletti, S	1
Carswell, CI	1
Goa, KL	1
Désir, B	1
Poitras, P	1
Tonini, M	1
Vigneri, S	1
Savarino, V	1
Scarpignato, C	1
Bown, RL	1
Samoyeau, R	1
Tani, N	1
Raoul, JL	1
Bretagne, JF	1
Ropert, A	1
Siproudhis, L	1
Heresbach, D	1
Gosselin, M	1
Barradell, LB	1
McTavish, D	1
Caruana, P	1
Bertelé, A	1
Franzé, A	1
Fishbeyn, VA	1
Benya, RV	1
Helander, HF	2
Rutgersson, K	2
Helander, KG	1
Pisegna, JP	1
Goel, AK	1
Sinha, S	1
Kumar, A	1
Chattopadhyay, K	1
Slimak, GG	1
Lajoie, C	1
Rhodes, JM	1
Collins, JS	1
Kennedy, TL	1
Johnston, CF	1
Sloan, JM	1
McIlrath, EM	1
Russell, C	1
Duek, SD	1
Barzilai, A	1
Pomelov, VS	1
Ganzha, PF	1
Lack, EE	1
Collen, MJ	2
Cornelius, MJ	2
David, E	1
Griffith, JL	1
Cummings, OW	1
Koop, H	2
Stumpf, M	1
Lamberts, R	1
Stöckmann, F	1
Creutzfeldt, W	1
Simon, TJ	1
Bradstreet, DC	1
Sobhani, I	1
Bonfils, SJ	1
Miller, LS	3
Vinayek, R	4
Frucht, H	5
London, JF	1
Stark, HA	1
Cederberg, C	1
Piper, DW	1
Yeomans, ND	1
Shearman, DJ	1
Amantea, MA	1
Sölvell, L	4
Uhl, D	1
De Giacomo, C	1
Fiocca, R	1
Licardi, G	1
Scotta, MS	1
Swartz, ML	1
Buhl, K	1
Clearfield, HR	1
Walan, A	5
Sakakibara, T	1
Inoue, K	1
Koizumi, T	1
Inoue, A	1
Kitanaka, H	1
Kaneko, E	1
Goldfain, D	2
le Bodic, MF	1
Lavergne, A	1
Galian, A	1
Modigliani, R	1
Zuckerman, S	1
Bardram, L	4
Stadil, F	4
Meijer, JL	1
McArthur, KA	1
Saeed, ZA	1
Stern, WR	1
Cortot, A	1
Travers, B	1
Isal, JP	2
Simon, B	2
Dammann, HG	2
Müller, P	2
Lloyd-Davies, KA	1
McArthur, KE	2
Vezzadini, P	1
Tomassetti, P	1
Marrano, D	1
Labò, G	1
Clissold, SP	1
Campoli-Richards, DM	1
Friedman, G	1
Thomsen, P	1
Deveney, CW	1
Deveney, KE	1
Cherner, JA	1
Howard, JM	1
Ciarleglio, CA	1
Stage, JG	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373]	Phase 4	72 participants (Actual)	Interventional	2003-03-31	Completed
Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis[NCT01524757]		48 participants (Anticipated)	Interventional	2012-03-31	Not yet recruiting
Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery[NCT00839488]	Phase 4	6 participants (Actual)	Interventional	2008-04-30	Terminated (stopped due to the chief of GS left the hopsital and the successor did't want to keep on this study)
Diagnostic Evaluation of Patients With Suspected Abnormalities of Gastric Secretion[NCT00001240]		0 participants	Observational	1989-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment

The Median Survival From the Time of Diagnosis.

Intervention	participants (Number)
Single Group	72

The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months

Article	Year
Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs, 2008, Volume: 68, Issue:11 Topics: Adult; Anti-Ulcer Agents; Duodenal Ulcer; Esomeprazole; Gastroesophageal Reflux; Helicobacter Infect	2008
Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs, 2003, Volume: 63, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents;	2003
Treating patients with acute gastrointestinal bleeding or rebleeding. Pharmacotherapy, 2003, Volume: 23, Issue:10 Pt 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials a	2003
Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease. European journal of gastroenterology & hepatology, 2005, Volume: 17, Issue:4 Topics: Adult; Anti-Ulcer Agents; Crohn Disease; Diagnosis, Differential; Diarrhea; Female; Gastric Acid; Ga	2005
[Zollinger-Ellison syndrome]. Wiener klinische Wochenschrift, 1984, Feb-17, Volume: 96, Issue:4 Topics: Benzimidazoles; Calcium; Cimetidine; Diarrhea; Duodenal Ulcer; Female; Fluorouracil; Gastrectomy; Ga	1984
[Proton pump blockers and their significance in gastroenterology]. Vnitrni lekarstvi, 1995, Volume: 41, Issue:8 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis, Peptic; Gas	1995
Management of patients with Zollinger-Ellison syndrome. Annual review of medicine, 1995, Volume: 46 Topics: Diagnostic Imaging; Gastrectomy; Gastric Acid; Histamine H2 Antagonists; Humans; Multiple Endocrine	1995
Enterochromaffin-like (ECL) cells and their growths: relationships to gastrin, reduced acid secretion and gastritis. Bailliere's clinical gastroenterology, 1993, Volume: 7, Issue:1 Topics: Animals; Carcinoid Tumor; Enterochromaffin Cells; Gastric Acid; Gastric Mucosa; Gastrins; Gastritis;	1993
Review article: the management of Zollinger-Ellison syndrome. Alimentary pharmacology & therapeutics, 1993, Volume: 7, Issue:5 Topics: Diagnosis, Differential; Gastric Acid; Gastrinoma; Gastrins; Histamine H2 Antagonists; Humans; Hydro	1993
Management of Zollinger-Ellison syndrome. The Gastroenterologist, 1994, Volume: 2, Issue:2 Topics: Gastric Acid; Humans; Omeprazole; Zollinger-Ellison Syndrome	1994
Acid pump blockers: what are their current therapeutic roles? Bailliere's clinical gastroenterology, 1993, Volume: 7, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Duodenal Ulcer; Gastroesophageal Reflux;	1993
[Lansoprazole--profile of a new proton pump inhibitor]. Leber, Magen, Darm, 1994, Volume: 24, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A	1994
Treatment of patients with Zollinger-Ellison syndrome. Clinical therapeutics, 1993, Volume: 15 Suppl B Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Clinical Trials as Topic; F	1993
[Risk for developing tumors in therapy with the proton pump inhibitor omeprazole]. Versicherungsmedizin, 1993, Aug-01, Volume: 45, Issue:4 Topics: Animals; Carcinogenicity Tests; Carcinoid Tumor; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulc	1993
[Omeprazole. Its pharmacology and therapeutic efficacy]. Deutsche medizinische Wochenschrift (1946), 1993, Feb-19, Volume: 118, Issue:7 Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Stomach Ulcer; Zollinger-Ellison Syndrome	1993
Surgery for acid suppression in the 1990s. Bailliere's clinical gastroenterology, 1993, Volume: 7, Issue:1 Topics: Anti-Ulcer Agents; Female; Gastric Acid; Gastric Mucosa; Helicobacter pylori; Humans; Intestinal Muc	1993
Lansoprazole: a proton pump inhibitor. The Annals of pharmacotherapy, 1996, Volume: 30, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Esophagitis; Humans;	1996
Proton-pump inhibitors for gastric acid-related disease. Cleveland Clinic journal of medicine, 1998, Volume: 65, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastric Acid; Helicobacter	1998
Zollinger-Ellison syndrome. Improved treatment options for this complex disorder. Postgraduate medicine, 1998, Volume: 104, Issue:1 Topics: Anti-Ulcer Agents; Combined Modality Therapy; Diagnosis, Differential; Enzyme Inhibitors; Gastrectom	1998
[25 years of gastric acid blockers]. Nederlands tijdschrift voor geneeskunde, 1999, Dec-11, Volume: 143, Issue:50 Topics: Anti-Ulcer Agents; Cimetidine; Dyspepsia; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans;	1999
[Indications and use of omeprazole in esophago-gastro-duodenal diseases]. Revista clinica espanola, 1999, Volume: 199, Issue:11 Topics: Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Esophageal Diseases; Esophagitis; Gastritis;	1999
[Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999]. Recenti progressi in medicina, 2000, Volume: 91, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents;	2000
Fundic gland polyps: a still elusive entity on the eve of the year 2000. Polish journal of pathology : official journal of the Polish Society of Pathologists, 2000, Volume: 51, Issue:1 Topics: Adenomatous Polyposis Coli; Anti-Ulcer Agents; Female; Gardner Syndrome; Gastric Fundus; Gastric Muc	2000
Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Digestion, 2000, Volume: 62, Issue:2-3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastric Ac	2000
Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2000, Volume: 14 Suppl D Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis, Peptic; Gas	2000
[Experience in the use of losek (omeprazole) in gastroenterology]. Terapevticheskii arkhiv, 2001, Volume: 73, Issue:7 Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Double	2001
Rabeprazole: an update of its use in acid-related disorders. Drugs, 2001, Volume: 61, Issue:15 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida	2001
Clinical pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2001, Volume: 33, Issue:7 Topics: Anti-Ulcer Agents; Drug Interactions; Esomeprazole; Humans; Omeprazole; Peptic Ulcer; Proton Pump In	2001
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. International journal of clinical practice, 2002, Volume: 56, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym	2002
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs, 1992, Volume: 44, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer;	1992
Role of acid suppressants in patients with Zollinger-Ellison syndrome. Alimentary pharmacology & therapeutics, 1991, Volume: 5 Suppl 1 Topics: Gastric Acid; Histamine H2 Antagonists; Humans; Omeprazole; Zollinger-Ellison Syndrome	1991
[Diagnosis and treatment of Zollinger-Ellison syndrome]. Klinicheskaia meditsina, 1991, Volume: 69, Issue:8 Topics: Gastrectomy; Histamine H2 Antagonists; Humans; Omeprazole; Vagotomy, Proximal Gastric; Zollinger-Ell	1991
[Anomalies of fundic argyrophil cell proliferation (enterochromaffin-like cells) in Zollinger-Ellison syndrome]. Gastroenterologie clinique et biologique, 1991, Volume: 15, Issue:5 ( Pt 2) Topics: Carcinoid Tumor; Enterochromaffin Cells; Female; Gastrins; Humans; Male; Omeprazole; Pyloric Antrum;	1991
[From acid secretion inhibition to enterochromaffin-like cell proliferation. Traps on the path]. Gastroenterologie clinique et biologique, 1991, Volume: 15, Issue:5 ( Pt 2) Topics: Adenocarcinoma; Carcinoid Tumor; Enterochromaffin Cells; Gastric Mucosa; Gastrins; Gastritis, Atroph	1991
Omeprazole. The New England journal of medicine, 1991, Apr-04, Volume: 324, Issue:14 Topics: Duodenal Ulcer; Gastric Acid; Gastric Mucosa; Humans; Omeprazole; Stomach Ulcer; Zollinger-Ellison S	1991
Use of omeprazole in patients with Zollinger-Ellison syndrome. Digestive diseases and sciences, 1991, Volume: 36, Issue:4 Topics: Humans; Omeprazole; Zollinger-Ellison Syndrome	1991
The clinical safety of omeprazole. Digestion, 1990, Volume: 47 Suppl 1 Topics: Humans; Omeprazole; Peptic Ulcer; Product Surveillance, Postmarketing; Zollinger-Ellison Syndrome	1990
[Omeprazole. A new substance for inhibiting acid production]. Medizinische Monatsschrift fur Pharmazeuten, 1990, Volume: 13, Issue:2 Topics: Animals; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Peptic Ulcer; Zollinger-Ellison Synd	1990
Clinical experience with omeprazole: assessment of efficacy and safety. Journal of gastroenterology and hepatology, 1989, Volume: 4 Suppl 2 Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zollinger-Elli	1989
New directions in the management of Zollinger-Ellison syndrome: a case study and review. The Mount Sinai journal of medicine, New York, 1989, Volume: 56, Issue:4 Topics: Adult; Combined Modality Therapy; Female; Gastrinoma; Histamine H2 Antagonists; Humans; Omeprazole;	1989
The clinical utility and safety of omeprazole. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Duodenal Ulcer; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Multicenter Studies as Topic;	1989
Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers. Digestion, 1989, Volume: 44 Suppl 1 Topics: Drug Administration Schedule; Duodenal Ulcer; Gastric Acid; Histamine H2 Antagonists; Humans; Omepra	1989
Recent advances in the management of gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology clinics of North America, 1989, Volume: 18, Issue:4 Topics: Cimetidine; Famotidine; Gastric Acid; Histamine H2 Antagonists; Humans; Nizatidine; Omeprazole; Para	1989
Clinical utility and safety of omeprazole. Methods and findings in experimental and clinical pharmacology, 1989, Volume: 11 Suppl 1 Topics: Animals; Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zolli	1989
Is there a need for strong gastric acid inhibition in clinical practice? Digestion, 1989, Volume: 44 Suppl 1 Topics: Anti-Ulcer Agents; Drug Administration Schedule; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazo	1989
Omeprazole. Bailliere's clinical gastroenterology, 1988, Volume: 2, Issue:3 Topics: Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Sto	1988
[Omeprazole]. Gastroenterologie clinique et biologique, 1987, Volume: 11, Issue:11 Topics: Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dose-Response Relationship, Drug; Esophagit	1987
Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome. Drugs, 1986, Volume: 32, Issue:1 Topics: Animals; Anti-Ulcer Agents; Benzimidazoles; Biological Availability; Drug Interactions; Gastric Acid	1986
Omeprazole. The American journal of gastroenterology, 1987, Volume: 82, Issue:3 Topics: Achlorhydria; Animals; Duodenal Ulcer; Humans; Omeprazole; Rats; Zollinger-Ellison Syndrome	1987
Medical treatment of peptic ulcers. Surgery annual, 1985, Volume: 17 Topics: Aluminum; Antacids; Anti-Ulcer Agents; Benzimidazoles; Bismuth; Cimetidine; Humans; Omeprazole; Para	1985

Article	Year
Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2005, Volume: 3, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis	2005
Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Alimentary pharmacology & therapeutics, 2006, Feb-01, Volume: 23, Issue:3 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Anti-Ulcer Agents; Benzimidazol	2006
[Substituted benzimidazoles--a new dimension in ulcer therapy?]. Wiener klinische Wochenschrift, 1984, Feb-17, Volume: 96, Issue:4 Topics: Benzimidazoles; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esoph	1984
[Comparative efficacy of lansoprazole and omeprazole on the intragastric pH measured over a period of 24 hours and on the basal]. Gastroenterologie clinique et biologique, 1994, Volume: 18, Issue:8-9 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Gastric Acid; Gastr	1994
Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Alimentary pharmacology & therapeutics, 1993, Volume: 7, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Follow-Up S	1993
Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Digestive diseases and sciences, 1993, Volume: 38, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Aged; Anti-Ulcer Agents;	1993
Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. Alimentary pharmacology & therapeutics, 1993, Volume: 7 Suppl 1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alanine Transaminase; Anti-Ulcer Agents; Aspar	1993
Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Duodenal Ulcer; Enzyme Inhibitors	1996
Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Enzyme I	1996
Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Alimentary pharmacology & therapeutics, 1998, Volume: 12, Issue:1 Topics: Adolescent; Adult; Aged; Anemia; Antacids; Anti-Ulcer Agents; Clinical Protocols; Female; Gastric Ac	1998
[Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment]. Gastroenterologie clinique et biologique, 1998, Volume: 22, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dose-Response Relationship, Drug; Enzyme Inhib	1998
Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study. The American journal of gastroenterology, 1999, Volume: 94, Issue:10 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Dose-	1999
Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology, 2000, Volume: 118, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Gas	2000
Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. Gastroenterologie clinique et biologique, 2002, Volume: 26, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric Acid; Ga	2002
Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs, 1992, Volume: 44, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Biological Availability; Duodenal Ulcer;	1992
Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology, 1992, Volume: 102, Issue:3 Topics: Adult; Aged; Cimetidine; Dose-Response Relationship, Drug; Duodenal Neoplasms; Famotidine; Female; F	1992
Role of acid suppressants in patients with Zollinger-Ellison syndrome. Alimentary pharmacology & therapeutics, 1991, Volume: 5 Suppl 1 Topics: Gastric Acid; Histamine H2 Antagonists; Humans; Omeprazole; Zollinger-Ellison Syndrome	1991
Omeprazole. The New England journal of medicine, 1991, Apr-04, Volume: 324, Issue:14 Topics: Duodenal Ulcer; Gastric Acid; Gastric Mucosa; Humans; Omeprazole; Stomach Ulcer; Zollinger-Ellison S	1991
Pharmacokinetics of oral and intravenous omeprazole in patients with the Zollinger-Ellison syndrome. Gastroenterology, 1991, Volume: 101, Issue:1 Topics: Administration, Oral; Adult; Aged; Biological Availability; Female; Gastric Acid; Half-Life; Humans;	1991
The clinical safety of omeprazole. Digestion, 1990, Volume: 47 Suppl 1 Topics: Humans; Omeprazole; Peptic Ulcer; Product Surveillance, Postmarketing; Zollinger-Ellison Syndrome	1990
Omeprazole. The Medical letter on drugs and therapeutics, 1990, Mar-09, Volume: 32, Issue:813 Topics: Animals; Carcinoid Tumor; Clinical Trials as Topic; Gastric Acid; Gastroesophageal Reflux; Humans; O	1990
Clinical experience with omeprazole: assessment of efficacy and safety. Journal of gastroenterology and hepatology, 1989, Volume: 4 Suppl 2 Topics: Duodenal Ulcer; Esophagitis, Peptic; Humans; Omeprazole; Peptic Ulcer; Stomach Ulcer; Zollinger-Elli	1989
The clinical utility and safety of omeprazole. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Duodenal Ulcer; Esophagitis, Peptic; Histamine H2 Antagonists; Humans; Multicenter Studies as Topic;	1989
The clinical safety of omeprazole. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Cimetidine; Clinical Trials as Topic; Esophagitis, Peptic; Humans; Liver Function Tests; Omeprazole;	1989
[Omeprazole in the therapy of acid-induced diseases]. Zeitschrift fur Gastroenterologie, 1987, Volume: 25 Suppl 3 Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Duodenal Ulcer; Eso	1987
[Therapeutic achlorhydria: for which diseases, when and for how long?]. Deutsche medizinische Wochenschrift (1946), 1988, Mar-31, Volume: 113, Issue:13 Topics: Achlorhydria; Clinical Trials as Topic; Double-Blind Method; Duodenal Ulcer; Esophagitis, Peptic; Hi	1988
Treatment of acid-peptic diseases by inhibition of gastric H+,K+-ATPase. Annual review of medicine, 1986, Volume: 37 Topics: Adenosine Triphosphatases; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic; Duodenal Ulc	1986
Omeprazole. Bailliere's clinical gastroenterology, 1988, Volume: 2, Issue:3 Topics: Clinical Trials as Topic; Duodenal Ulcer; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Sto	1988
[Omeprazole]. Gastroenterologie clinique et biologique, 1987, Volume: 11, Issue:11 Topics: Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dose-Response Relationship, Drug; Esophagit	1987

Article	Year
Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract. JAMA surgery, 2018, 03-01, Volume: 153, Issue:3 Topics: Adult; Bile Duct Neoplasms; Disease-Free Survival; Female; Gastrinoma; Gastrins; Hepatectomy; Humans	2018
Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. Pancreas, 2013, Volume: 42, Issue:6 Topics: Achlorhydria; Adolescent; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; False Positive Reactions; Fe	2013
From hypomagnesaemia to Zollinger-Ellison syndrome: an adverse effect of a proton pump inhibitor. BMJ case reports, 2014, Oct-01, Volume: 2014 Topics: Duodenal Neoplasms; Duodenal Ulcer; Gastrinoma; Humans; Magnesium; Male; Middle Aged; Omeprazole; Pe	2014
Long-term follow-up of a child with primary lymph node gastrinoma and Zollinger-Ellison syndrome. Journal of pediatric surgery, 2011, Volume: 46, Issue:5 Topics: Abdominal Pain; Anti-Ulcer Agents; Child; Combined Modality Therapy; Diarrhea; Duodenal Ulcer; Follo	2011
[Visual documentation of the stability of intravenous solutions of omeprazole (Losec) and pantoprazole (Pantoloc)]. Wiener medizinische Wochenschrift (1946), 2002, Volume: 152, Issue:21-22 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Stability; Drug Sto	2002
Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. The American journal of gastroenterology, 2003, Volume: 98, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Benzimidazoles; Dose-Response Relatio	2003
Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole. European journal of gastroenterology & hepatology, 2003, Volume: 15, Issue:7 Topics: Achlorhydria; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cell Division; Drug Administration Schedul	2003
[Hereditary neuroendocrine gastroenteropancreatic tumors and multiple endocrine neoplasia type 1]. Deutsche medizinische Wochenschrift (1946), 2004, Mar-26, Volume: 129, Issue:13 Topics: Anti-Ulcer Agents; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormon	2004
Control of acute Zollinger-Ellison syndrome with intravenous omeprazole. Lancet (London, England), 1982, Nov-27, Volume: 2, Issue:8309 Topics: Acute Disease; Adult; Benzimidazoles; Humans; Injections, Intravenous; Male; Omeprazole; Zollinger-E	1982
Reduction of gastric hypersecretion in Zollinger-Ellison syndrome with omeprazole. Lancet (London, England), 1983, Jan-01, Volume: 1, Issue:8314-5 Topics: Adult; Benzimidazoles; Depression, Chemical; Female; Gastric Juice; Humans; Male; Middle Aged; Omepr	1983
Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists. The New England journal of medicine, 1984, Mar-22, Volume: 310, Issue:12 Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Cimetidine; Drug Evaluation; Drug Resistance; Gastric Acid	1984
The SSAT-AGA (Society for Surgery of the Alimentary Tract-American Gastroenterological Association). New Orleans, May 20-23, 1984. Surgical gastroenterology, 1984, Volume: 3, Issue:2 Topics: Animals; Benzimidazoles; Colitis, Ulcerative; Colon; Common Bile Duct; Crohn Disease; Digestive Syst	1984
[Gastric secretory, ultrastructural and pH changes during prolonged treatment with omeprazole in a severe form of Zollinger-Ellison syndrome]. Gastroenterologie clinique et biologique, 1984, Volume: 8, Issue:12 Topics: Adult; Benzimidazoles; Gastric Acid; Gastric Fundus; Gastric Juice; Gastric Mucosa; Humans; Hydrogen	1984
[Omeprazole and inhibition of gastric acid secretion]. Recenti progressi in medicina, 1984, Volume: 75, Issue:4 Topics: Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Humans; Omeprazole; Zollinger-Ellison Syndrome	1984
Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma. JAMA, 1994, May-11, Volume: 271, Issue:18 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Blood Chemical Analysis; Combined Modali	1994
Successful pregnancy in association with Zollinger-Ellison syndrome. American journal of obstetrics and gynecology, 1995, Volume: 173, Issue:3 Pt 1 Topics: Adult; Anti-Ulcer Agents; Female; Gastric Acid; Gastrins; Humans; Nausea; Omeprazole; Pregnancy; Pre	1995
Second proton-pump inhibitor marketed. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1995, Aug-01, Volume: 52, Issue:15 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis; Humans; Lan	1995
[Stenosing esophagitis in Zollinger-Ellison syndrome]. Gastroenterologie clinique et biologique, 1994, Volume: 18, Issue:11 Topics: Esophageal Stenosis; Esophagectomy; Esophagitis; Gastrectomy; Humans; Male; Middle Aged; Omeprazole;	1994
Vitamin B12 malabsorption and omeprazole therapy. Journal of the American College of Nutrition, 1994, Volume: 13, Issue:6 Topics: Dose-Response Relationship, Drug; Humans; Intestinal Absorption; Malabsorption Syndromes; Omeprazole	1994
[Possibilities of the use of present-day antisecretory preparation omeprazole]. Klinicheskaia meditsina, 1994, Volume: 72, Issue:6 Topics: Adult; Aged; Aluminum Hydroxide; Antacids; Benzilates; Benzocaine; Choline; Cimetidine; Drug Combina	1994
Hypergastrinaemia. The British journal of surgery, 1994, Volume: 81, Issue:7 Topics: Gastrins; Humans; Omeprazole; Zollinger-Ellison Syndrome	1994
Gastric endocrine cell evolution in patients with Zollinger-Ellison syndrome. Influence of gastrinoma growth and long-term omeprazole treatment. Digestive diseases and sciences, 1993, Volume: 38, Issue:7 Topics: Adult; Aged; APUD Cells; Chi-Square Distribution; Chronic Disease; Female; Gastrinoma; Gastrins; Hum	1993
[What are the indications for proton pump inhibitors? R. Arnold, Marburg, elaborates on the clinical aspects of the controversy regarding lansoprazole. Interview by Gerrit Lichtenberg]. Fortschritte der Medizin, 1994, Jan-20, Volume: 112, Issue:1-2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Carcinogenicity Tests; Carcinoi	1994
[Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome]. Gastroenterologie clinique et biologique, 1994, Volume: 18, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Anti-Ulcer Agents; Depression,	1994
Diagnostic value of serum pepsinogen C in patients with raised serum concentrations of pepsinogen A. Gut, 1993, Volume: 34, Issue:10 Topics: Adult; Aged; Clinical Enzyme Tests; Duodenal Ulcer; Esophagitis, Peptic; Female; Gastritis, Hypertro	1993
Efficacy of long-term therapy with low doses of omeprazole in the control of gastric acid secretion in Zollinger-Ellison syndrome patients. Alimentary pharmacology & therapeutics, 1993, Volume: 7, Issue:2 Topics: Adult; Drug Administration Schedule; Famotidine; Female; Gastric Acid; Humans; Male; Middle Aged; Om	1993
A prospective study of the effectiveness of low dose omeprazole as initial therapy in Zollinger-Ellison syndrome. Alimentary pharmacology & therapeutics, 1996, Volume: 10, Issue:1 Topics: Adult; Aged; Anti-Ulcer Agents; Enzyme Inhibitors; Female; Gastric Acid; Humans; Male; Middle Aged;	1996
Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy. Gastroenterology, 1997, Volume: 112, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Cohort Studies; Female; Gastric Acid; Gastric Acidity De	1997
Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. The American journal of medicine, 1998, Volume: 104, Issue:5 Topics: Achlorhydria; Adenosine Triphosphatases; Adolescent; Adult; Aged; Anti-Ulcer Agents; Drug Monitoring	1998
Cushing's syndrome due to ectopic adrenocorticotropic hormone production by a non-metastatic gastrinoma after long-term conservative treatment of Zollinger-Ellison syndrome. Italian journal of gastroenterology and hepatology, 1998, Volume: 30, Issue:6 Topics: Adrenocorticotropic Hormone; Aged; Anti-Ulcer Agents; Cushing Syndrome; Female; Gastrinoma; Gastrins	1998
Intramucosal cysts in the gastric body of patients with Zollinger-Ellison syndrome. Human pathology, 2000, Volume: 31, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aging; Biopsy; Cell Division; Cysts; Enterochromaffin Cells; Female;	2000
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:1 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Enterochromaffin-like Cells; Enzyme Inhibitors; Fema	2001
The safety of proton pump inhibitors. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:5 Topics: Carcinoid Tumor; Cell Transformation, Neoplastic; Enzyme Inhibitors; Gastric Acid; Humans; Omeprazol	2001
Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:10 Topics: Anti-Ulcer Agents; Costs and Cost Analysis; Histamine H2 Antagonists; Humans; Italy; Omeprazole; Pro	2001
Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Alimentary pharmacology & therapeutics, 2001, Volume: 15, Issue:11 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Dose-Response Relationship, Drug; Drug Administratio	2001
Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome. Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2001, Volume: 15, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric Ac	2001
Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. The American journal of gastroenterology, 2001, Volume: 96, Issue:12 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Dose-Res	2001
Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors. Alimentary pharmacology & therapeutics, 2002, Volume: 16, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Dose-Response Relationship, Drug;	2002
Protonix. First i.v. proton pump inhibitor approved. Nursing, 2002, Volume: 32, Issue:2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clinical Trials as Topic	2002
Pantoprazole IV (Protonix IV). The Medical letter on drugs and therapeutics, 2002, Apr-29, Volume: 44, Issue:1129 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clinical Trials as Topic; Drug Approval; Fe	2002
[Application of proton pump inhibitor to special conditions; Zollinger-Ellison syndrome]. Nihon rinsho. Japanese journal of clinical medicine, 1992, Volume: 50, Issue:1 Topics: Adenosine Triphosphatases; Adult; Combined Modality Therapy; Depression, Chemical; Gastric Acid; H(+	1992
Zollinger-Ellison syndrome, antisecretory treatment, and body weight. Digestive diseases and sciences, 1992, Volume: 37, Issue:8 Topics: Body Weight; Female; Gastric Mucosa; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omeprazole	1992
Focal oxyntic gland atrophy with endocrine cell hyperplasia in Zollinger-Ellison syndrome during omeprazole treatment. Histopathology, 1992, Volume: 21, Issue:4 Topics: Adult; Atrophy; Endocrine Glands; Female; Humans; Hyperplasia; Male; Middle Aged; Omeprazole; Pariet	1992
Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology, 1992, Volume: 103, Issue:5 Topics: Adult; Aged; Female; Gastric Acid; Gastrins; Humans; Longitudinal Studies; Male; Middle Aged; Omepra	1992
Stereologic investigations of human gastric mucosa. II. Oxyntic mucosa from patients with Zollinger-Ellison syndrome. Scandinavian journal of gastroenterology, 1992, Volume: 27, Issue:10 Topics: Adolescent; Adult; Age Factors; Aged; Biopsy; Cell Count; Evaluation Studies as Topic; Female; Gastr	1992
Total gastrectomy in Zollinger Ellison syndrome: does it have no role today? The Journal of the Association of Physicians of India, 1992, Volume: 40, Issue:4 Topics: Cost-Benefit Analysis; Developing Countries; Gastrectomy; Humans; India; Omeprazole; Patient Complia	1992
Criteria for use of omeprazole in adult inpatients and outpatients. Clinical pharmacy, 1992, Volume: 11, Issue:2 Topics: Adult; Barrett Esophagus; Duodenal Ulcer; Education, Pharmacy, Continuing; Esophagitis, Peptic; Huma	1992
The medical management of Zollinger-Ellison syndrome. The Quarterly journal of medicine, 1991, Volume: 78, Issue:287 Topics: Histamine H2 Antagonists; Humans; Omeprazole; Zollinger-Ellison Syndrome	1991
Changing patterns in presentation and management of the Zollinger-Ellison syndrome in Northern Ireland, 1970-1988. The Quarterly journal of medicine, 1991, Volume: 78, Issue:287 Topics: Adult; Aged; Female; Gastric Acid; Gastrins; Histamine H2 Antagonists; Humans; Male; Middle Aged; Om	1991
[Treatment of Zollinger-Ellison syndrome]. Harefuah, 1991, Apr-01, Volume: 120, Issue:7 Topics: Female; Histamine H2 Antagonists; Humans; Liver Neoplasms; Middle Aged; Omeprazole; Streptozocin; Va	1991
The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells. Gastroenterology, 1990, Volume: 99, Issue:4 Topics: Adult; Cell Count; Female; Gastric Mucosa; Gastrins; Humans; Male; Middle Aged; Omeprazole; Parietal	1990
Development of sustained achlorhydria in a patient with the Zollinger-Ellison syndrome treated with omeprazole. Gastroenterology, 1991, Volume: 101, Issue:1 Topics: Achlorhydria; Atrophy; Female; Gastric Mucosa; Humans; Middle Aged; Omeprazole; Zollinger-Ellison Sy	1991
Antral Helicobacter pylori-like organisms in different states of gastric acid secretion. Digestion, 1991, Volume: 48, Issue:4 Topics: Adolescent; Adult; Aged; Duodenal Ulcer; Esophagitis, Peptic; Female; Gastric Acid; Gastritis; Helic	1991
Comparative tolerability profile of omeprazole in clinical trials. Digestive diseases and sciences, 1991, Volume: 36, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Cimet	1991
Reflux esophagitis in patients with Zollinger-Ellison syndrome. Gastroenterology, 1990, Volume: 98, Issue:2 Topics: Adult; Aged; Esophagitis, Peptic; Female; Histamine H2 Antagonists; Humans; Male; Middle Aged; Omepr	1990
Intravenous omeprazole in patients with Zollinger-Ellison syndrome undergoing surgery. Gastroenterology, 1990, Volume: 99, Issue:1 Topics: Adult; Aged; Female; Gastric Acid; Histamine H2 Antagonists; Humans; Injections, Intravenous; Intrao	1990
Omeprazole and acid peptic disease. The Medical journal of Australia, 1991, Mar-18, Volume: 154, Issue:6 Topics: Animals; Drug Administration Schedule; Duodenal Ulcer; Esophagitis, Peptic; Gastric Acid; Humans; Om	1991
Omeprazole treatment of severe peptic disease associated with antral G cell hyperfunction and hyperpepsinogenemia I in an infant. The Journal of pediatrics, 1990, Volume: 117, Issue:6 Topics: Administration, Oral; Biopsy; Child, Preschool; Endoscopy, Gastrointestinal; Female; Gastrins; Human	1990
Losec (omeprazole/MSD). Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates, 1990,Spring, Volume: 12, Issue:4 Topics: Delayed-Action Preparations; Humans; Omeprazole; Zollinger-Ellison Syndrome	1990
Omeprazole: a new approach to gastric acid suppression. American family physician, 1990, Volume: 41, Issue:4 Topics: Esophagitis, Peptic; Gastric Acid; Gastroesophageal Reflux; Humans; Omeprazole; Zollinger-Ellison Sy	1990
[A case of Zollinger-Ellison syndrome successfully treated with an H+-K+ ATPase inhibitor]. Gan no rinsho. Japan journal of cancer clinics, 1989, Volume: 35, Issue:10 Topics: Adenosine Triphosphatases; Gastrinoma; Gastrins; H(+)-K(+)-Exchanging ATPase; Humans; Male; Middle A	1989
Gastric carcinoid tumours in patients with Zollinger-Ellison syndrome on long-term omeprazole. Lancet (London, England), 1989, Apr-08, Volume: 1, Issue:8641 Topics: Carcinoid Tumor; Humans; Long-Term Care; Male; Middle Aged; Omeprazole; Stomach Neoplasms; Zollinger	1989
Long-term follow up of patients with Zollinger-Ellison syndrome (ZES). Acta chirurgica Scandinavica, 1989, Volume: 155, Issue:8 Topics: Aged; Female; Follow-Up Studies; Gastrinoma; Gastrins; Histamine H2 Antagonists; Humans; Male; Middl	1989
Effects of omeprazole on acid secretion and acid-related symptoms in patients with Zollinger-Ellison syndrome. Scandinavian journal of gastroenterology. Supplement, 1989, Volume: 166 Topics: Adult; Aged; Cimetidine; Female; Gastric Acid; Gastrins; Humans; Long-Term Care; Male; Middle Aged;	1989
Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study. Gastroenterology, 1989, Volume: 97, Issue:4 Topics: Adult; Aged; Drug Administration Schedule; Female; Gastric Acid; Gastric Mucosa; Humans; Intestinal	1989
Summary of the 34th meeting of the Food and Drug Administration Gastrointestinal Drugs Advisory Committee. March 15 and 16, 1989 (omeprazole and domperidone). The American journal of gastroenterology, 1989, Volume: 84, Issue:11 Topics: Animals; Diabetes Complications; Domperidone; Duodenal Ulcer; Gastroesophageal Reflux; Humans; Omepr	1989
Effectiveness of omeprazole in seven patients with Zollinger-Ellison syndrome resistant to histamine H2-receptor antagonists. Digestive diseases and sciences, 1986, Volume: 31, Issue:7 Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Benzodiazepinones; Cimetidine; Drug Resistance; Drug Thera	1986
Omeprazole in the treatment of Zollinger-Ellison syndrome: a 4-year international study. Alimentary pharmacology & therapeutics, 1988, Volume: 2, Issue:1 Topics: Adolescent; Adult; Aged; Female; Gastric Acid; Humans; Male; Middle Aged; Omeprazole; Zollinger-Elli	1988
Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors. Scandinavian journal of gastroenterology. Supplement, 1986, Volume: 125 Topics: Adenosine Triphosphatases; Digestive System Diseases; Duodenal Ulcer; Esophagitis, Peptic; Gastric A	1986
Life-threatening gastrointestinal hemorrhage with omeprazole. Digestive diseases and sciences, 1988, Volume: 33, Issue:6 Topics: Administration, Oral; Adult; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Omeprazole; Zol	1988
Present experiences with omeprazole in the Zollinger-Ellison syndrome. Scandinavian journal of gastroenterology. Supplement, 1986, Volume: 118 Topics: Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Gastrins; Humans; Omeprazole; Peptic Ulcer; Time Fa	1986
Safety aspects of omeprazole. Scandinavian journal of gastroenterology. Supplement, 1986, Volume: 118 Topics: Alanine Transaminase; Anti-Ulcer Agents; Benzimidazoles; Creatinine; Dose-Response Relationship, Dru	1986
[Omeprazole and peptic ulcer. Profile of a new active agent]. Fortschritte der Medizin, 1987, Jan-20, Volume: 105, Issue:2 Topics: Humans; Omeprazole; Peptic Ulcer; Zollinger-Ellison Syndrome	1987
Omeprazole in the Zollinger-Ellison syndrome. Scandinavian journal of gastroenterology, 1986, Volume: 21, Issue:3 Topics: Adult; Anti-Ulcer Agents; Benzimidazoles; Gastric Acid; Humans; Male; Middle Aged; Omeprazole; Secre	1986
Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome. Digestion, 1986, Volume: 35 Suppl 1 Topics: Female; Gastric Mucosa; Gastrins; Humans; Hyperplasia; Male; Omeprazole; Time Factors; Zollinger-Ell	1986
Oxyntic mucosa histology in omeprazole-treated patients suffering from duodenal ulcer or Zollinger-Ellison syndrome. Digestion, 1986, Volume: 35 Suppl 1 Topics: Adult; Biopsy; Duodenal Ulcer; Female; Gastric Mucosa; Humans; Male; Middle Aged; Omeprazole; Pariet	1986
Omeprazole: effective, convenient therapy for Zollinger-Ellison syndrome. Gastroenterology, 1985, Volume: 88, Issue:4 Topics: Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Female; Gastric Acid; Humans; Male; Middle Aged; Ome	1985
[Omeprazole treatment in the Zollinger-Ellison syndrome]. Ugeskrift for laeger, 1985, Mar-04, Volume: 147, Issue:10 Topics: Adult; Benzimidazoles; Humans; Male; Middle Aged; Omeprazole; Zollinger-Ellison Syndrome	1985

omeprazole and Zollinger-Ellison Syndrome